This case was reported by a physician (specialist), via a sales
representative, and described the occurrence of exacerbation of progressive
multifocal leukoencephalopathy (progressive PML) in a 45-year-old male
patient who received dolutegravir (Tivicay) (ViiV healthcare limited) for
human immunodeficiency virus. 
Co-suspect medication included tenofovir/emtricitabine (Truvada). Concurrent
medications included Mefloquine and Mirtazapine. 
On an unknown date, the patient started dolutegravir (unknown route and dose)
and Truvada (unknown route and dose). It was reported that the patient had
'impressive' response with the treatment. However, At an unknown time after
starting dolutegravir and Truvada, the patient experienced exacerbation of
progressive multifocal leukoencephalopathy (progressive PML) and immune
reconstitution inflammatory syndrome (JC virus in CSF). It was reported that
the patient had received approval to begin treatment with Maraviroc. The
patient was hospitalised. At the time of reporting, the outcome of the events
was unknown.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 304 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
Case correction was made on 17 September 2014: 
Event was amended from 'progressive multifocal leukoencephalopathy' to
'exacerbation of progressive multifocal leukoencephalopathy'.
Follow-up information received on 18 September 2014:
The doctor confirmed that the patient definitely had PML when he presented to
the hospital. At the time of reporting, the patient had stabilised with
significant improvement. Maraviroc was commenced on Thursday 11 September.